|
Dendritic cells (DC) is the most powerful antigen presenting cells(APCs) in vivo, which can activate na?ve T lymphocyte and stimulate T lymphocyte proliferation, activation, induction of specific immune response to kill tumor cells. DC can not only start antigen-specific T cell recognition and kill tumor cells, but also stimulate the immune memory protection which plays a protective effect when the patient is once again under the attack of tumor cells. DC is such a key element in the process of the activation of specific immunity that the immune system will not recognize and kill tumor cells without antigen processing by DC. Therefore the participation of DC can make anti-tumor immunotherapy more effective.
Cytokine-induced killer cells (CIK),a type of immune effector cells, become an more effective innovative cellular immunotherapy after LAK cells and tumor-infiltrating lymphocytes (TIL) immunotherapy appears . Autologous T-lymphocytes collected and isolated from peripheral blood can be induced activation by the addition of cytokines such as IL-2 and CD3 monoclonal antibodies in vitro. Infusion of a large number of activated T lymphocytes to patients play the anti-tumor role.
DC , which is a type of antigen presenting cell , in itself does not have anti-tumor effect, but can start specific anti-tumor immunity. CIK cells acting as effector cells can directly kill tumor cells, but this effect is non-specific for CIK cells cannot recognize tumor cells. DC-CIK treatment is a reasonable combination of the two effects ,which can induce a more effective anti-tumor immunity.
|
